{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:15:08Z","timestamp":1772165708283,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T00:00:00Z","timestamp":1686268800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T00:00:00Z","timestamp":1686268800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lymphoproliferative disorder represents a heterogeneous clinicopathological spectrum characterized by uncontrolled proliferation of lymphocytes. Immunodeficiency is a major trigger of its development. While induction of immunodeficiency is a well-known adverse effect of temozolomide therapy, development of lymphoproliferative disorder following temozolomide therapy has not previously been described.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A patient with brainstem glioma developed constitutional symptoms, pancytopenia, splenomegaly and generalized lymphadenopathy during the 2nd cycle of maintenance therapy following induction therapy with temozolomide. Epstein-Barr virus-infected lymphocytes were observed histopathologically and \u201cother iatrogenic immunodeficiency-associated lymphoproliferative disorder\u201d (OIIA-LPD) was diagnosed. Although discontinuation of temozolomide led to rapid remission, relapse was observed 4\u00a0months later. CHOP chemotherapy was induced, resulting in secondary remission. Vigilant follow-up for another 14\u00a0months showed radiologically stable brainstem glioma and no further recurrence of OIIA-LPD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This is the first report documenting OIIA-LPD during temozolomide administration. Timely diagnosis of the disease and discontinuation of the causative agent were considered to be the management of choice. Close monitoring for relapse should be continued. Finding a balance between glioma management and controlling the remission of OIIA-LPD remains to be clarified.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12883-023-03274-8","type":"journal-article","created":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T03:02:03Z","timestamp":1686279723000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Lymphoproliferative disorder during temozolomide therapy; a representative case of a formidable complication and management challenges"],"prefix":"10.1186","volume":"23","author":[{"given":"Daisuke","family":"Sato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokazu","family":"Takami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsaku","family":"Takayanagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Taoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reiko","family":"Matsuura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shota","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhito","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,9]]},"reference":[{"issue":"11","key":"3274_CR1","doi-asserted-by":"publisher","first-page":"5181","DOI":"10.21873\/anticanres.16024","volume":"42","author":"J Styczynski","year":"2022","unstructured":"Styczynski J, Sadlok J, Styczynski T, Marjanska A, Richert-Przygonska M. Management of resistant post-transplant lymphoproliferative disorder: CAR-T is a new option. Anticancer Res. 2022;42(11):5181\u20136. https:\/\/doi.org\/10.21873\/anticanres.16024.","journal-title":"Anticancer Res"},{"issue":"18","key":"3274_CR2","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1182\/blood-2018-04-842559","volume":"132","author":"Y Natkunam","year":"2018","unstructured":"Natkunam Y, Gratzinger D, Chadburn A, Goodlad JR, Chan JKC, Said J, et al. Immunodeficiency-associated lymphoproliferative disorders: time for reappraisal? Blood. 2018;132(18):1871\u20138. https:\/\/doi.org\/10.1182\/blood-2018-04-842559.","journal-title":"Blood"},{"key":"3274_CR3","doi-asserted-by":"publisher","unstructured":"Ogawa A, Nakagawa T, Kumaki Y, Hosoya T, Oda G, Mori M, et al. Spontaneous regression of breast lymphoproliferative disorders after withdrawal of methotrexate in rheumatoid arthritis patients with Epstein-Barr virus infection: a case report and review of the literature. J Med Case Rep. 2022;16 1:49; https:\/\/doi.org\/10.1186\/s13256-022-03274-1.","DOI":"10.1186\/s13256-022-03274-1"},{"issue":"2","key":"3274_CR4","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3960\/jslrt.19007","volume":"59","author":"M Tokuhira","year":"2019","unstructured":"Tokuhira M, Tamaru JI, Kizaki M. Clinical management for other iatrogenic immunodeficiency-associated lymphoproliferative disorders. J Clin Exp Hematop. 2019;59(2):72\u201392. https:\/\/doi.org\/10.3960\/jslrt.19007.","journal-title":"J Clin Exp Hematop"},{"key":"3274_CR5","doi-asserted-by":"publisher","unstructured":"Salem AE, Zaki YH, El-Hussieny G, ElNoueam KI, Shaaban AM, Koppula BR, et al. An Overview of selected rare B-cell lymphoproliferative disorders: Imaging, histopathologic, and clinical features. Cancers (Basel). 2021;13 22;\u00a0https:\/\/doi.org\/10.3390\/cancers13225853.","DOI":"10.3390\/cancers13225853"},{"key":"3274_CR6","doi-asserted-by":"publisher","unstructured":"Toyonaga H, Fukushima M, Shimeno N, Inokuma T. Methotrexate-associated lymphoproliferative disorder in the stomach and duodenum: a case report. BMC Gastroenterol. 2019;19 1:62; https:\/\/doi.org\/10.1186\/s12876-019-0982-4.","DOI":"10.1186\/s12876-019-0982-4"},{"issue":"10","key":"3274_CR7","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987\u201396. https:\/\/doi.org\/10.1056\/NEJMoa043330.","journal-title":"N Engl J Med"},{"issue":"6","key":"3274_CR8","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1093\/neuonc\/noab240","volume":"24","author":"AK Park","year":"2022","unstructured":"Park AK, Waheed A, Forst DA, Al-Samkari H. Characterization and prognosis of temozolomide-induced aplastic anemia in patients with central nervous system malignancies. Neuro Oncol. 2022;24(6):964\u201373. https:\/\/doi.org\/10.1093\/neuonc\/noab240.","journal-title":"Neuro Oncol"},{"issue":"9","key":"3274_CR9","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1200\/JCO.1998.16.9.3037","volume":"16","author":"HS Nicholson","year":"1998","unstructured":"Nicholson HS, Krailo M, Ames MM, Seibel NL, Reid JM, Liu-Mares W, et al. Phase I study of temozolomide in children and adolescents with recurrent solid tumors: a report from the Children\u2019s Cancer Group. J Clin Oncol. 1998;16(9):3037\u201343. https:\/\/doi.org\/10.1200\/JCO.1998.16.9.3037.","journal-title":"J Clin Oncol"},{"issue":"6","key":"3274_CR10","doi-asserted-by":"publisher","first-page":"8663","DOI":"10.3892\/ol.2018.8422","volume":"15","author":"P Liu","year":"2018","unstructured":"Liu P, Li P, Lei T, Qu L, Huang H, Mu Q. Acute lymphoblastic leukemia following temozolomide treatment in a patient with glioblastoma: a case report and review of the literature. Oncol Lett. 2018;15(6):8663\u20138. https:\/\/doi.org\/10.3892\/ol.2018.8422.","journal-title":"Oncol Lett"},{"issue":"4","key":"3274_CR11","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.jocn.2013.07.032","volume":"21","author":"KN Chou","year":"2014","unstructured":"Chou KN, Lin YC, Liu MY, Chang PY. Temozolomide-related acute lymphoblastic leukemia with translocation (4;11)(q21;q23) in a glioblastoma patient. J Clin Neurosci. 2014;21(4):701\u20134. https:\/\/doi.org\/10.1016\/j.jocn.2013.07.032.","journal-title":"J Clin Neurosci"},{"issue":"5","key":"3274_CR12","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1111\/j.1365-2141.2011.08641.x","volume":"154","author":"M Ogura","year":"2011","unstructured":"Ogura M, Todo T, Tanaka M, Nannya Y, Ichikawa M, Nakamura F, et al. Temozolomide may induce therapy-related acute lymphoblastic leukaemia. Br J Haematol. 2011;154(5):663\u20135. https:\/\/doi.org\/10.1111\/j.1365-2141.2011.08641.x.","journal-title":"Br J Haematol"},{"issue":"1","key":"3274_CR13","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00280-011-1679-8","volume":"69","author":"JL Villano","year":"2012","unstructured":"Villano JL, Letarte N, Yu JM, Abdur S, Bressler LR. Hematologic adverse events associated with temozolomide. Cancer Chemother Pharmacol. 2012;69(1):107\u201313. https:\/\/doi.org\/10.1007\/s00280-011-1679-8.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"3274_CR14","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/s10014-014-0210-4","volume":"32","author":"H Takami","year":"2015","unstructured":"Takami H, Mukasa A, Ikemura M, Shibahara J, Takahashi M, Momose T, et al. Findings from positron emission tomography and genetic analyses for cerebellar liponeurocytoma. Brain Tumor Pathol. 2015;32(3):210\u20135. https:\/\/doi.org\/10.1007\/s10014-014-0210-4.","journal-title":"Brain Tumor Pathol"},{"issue":"3","key":"3274_CR15","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/j.1349-7006.2011.02175.x","volume":"103","author":"A Mukasa","year":"2012","unstructured":"Mukasa A, Takayanagi S, Saito K, Shibahara J, Tabei Y, Furuya K, et al. Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients. Cancer Sci. 2012;103(3):587\u201392. https:\/\/doi.org\/10.1111\/j.1349-7006.2011.02175.x.","journal-title":"Cancer Sci"},{"key":"3274_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s10014-022-00448-z","author":"H Takami","year":"2022","unstructured":"Takami H, Mukasa A, Takayanagi S, Koike T, Matsuura R, Ikemura M, et al. Morphologically, genetically and spatially mixed astrocytoma and oligodendroglioma; chronological acquisition of 1p\/19q codeletion and CDKN2A deletion: a case report. Brain Tumor Pathol. 2022. https:\/\/doi.org\/10.1007\/s10014-022-00448-z.","journal-title":"Brain Tumor Pathol"},{"issue":"12","key":"3274_CR17","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1093\/annonc\/mdg371","volume":"14","author":"M Brada","year":"2003","unstructured":"Brada M, Viviers L, Abson C, Hines F, Britton J, Ashley S, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol. 2003;14(12):1715\u201321. https:\/\/doi.org\/10.1093\/annonc\/mdg371.","journal-title":"Ann Oncol"},{"issue":"1","key":"3274_CR18","doi-asserted-by":"publisher","first-page":"193","DOI":"10.4143\/crt.2015.473","volume":"49","author":"BS Kim","year":"2017","unstructured":"Kim BS, Seol HJ, Nam DH, Park CK, Kim IH, Kim TM, et al. Concurrent Concurrent chemoradiotherapy with temozolomide followed by adjuvant temozolomide for newly diagnosed glioblastoma patients: a petrospective multicenter observation study in Korea. Cancer Res Treat. 2017;49(1):193\u2013203. https:\/\/doi.org\/10.4143\/crt.2015.473.","journal-title":"Cancer Res Treat"},{"issue":"5","key":"3274_CR19","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1111\/cas.14811","volume":"112","author":"N Kobayashi","year":"2021","unstructured":"Kobayashi N, Takeda Y, Okubo N, Suzuki A, Tokuhisa M, Hiroshima Y, et al. Phase II study of temozolomide monotherapy in patients with extrapulmonary neuroendocrine carcinoma. Cancer Sci. 2021;112(5):1936\u201342. https:\/\/doi.org\/10.1111\/cas.14811.","journal-title":"Cancer Sci"},{"issue":"3","key":"3274_CR20","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1002\/ccr3.3860","volume":"9","author":"F Ata","year":"2021","unstructured":"Ata F, Akkam Veettil SF, Gaber M, Omar NE, Madani A, Mah Afifi H, et al. Fatal temozolomide induced aplastic anemia in a female with Glioblastoma multiforme\u202f: a case report and literature review. Clin Case Rep. 2021;9(3):1641\u20136. https:\/\/doi.org\/10.1002\/ccr3.3860.","journal-title":"Clin Case Rep"},{"issue":"27","key":"3274_CR21","doi-asserted-by":"publisher","first-page":"4518","DOI":"10.1200\/JCO.2008.18.8177","volume":"26","author":"B Neyns","year":"2008","unstructured":"Neyns B, Cordera S, Joosens E, Pouratian N. Non-Hodgkin\u2019s lymphoma in patients with glioma treated with temozolomide. J Clin Oncol. 2008;26(27):4518\u20139. https:\/\/doi.org\/10.1200\/JCO.2008.18.8177.","journal-title":"J Clin Oncol"},{"issue":"2","key":"3274_CR22","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s00428-016-2030-x","volume":"470","author":"K Ejima-Yamada","year":"2017","unstructured":"Ejima-Yamada K, Oshiro Y, Okamura S, Fujisaki T, Mihashi Y, Tamura K, et al. Epstein-Barr virus infection and gene promoter hypermethylation in rheumatoid arthritis patients with methotrexate-associated B cell lymphoproliferative disorders. Virchows Arch. 2017;470(2):205\u201315. https:\/\/doi.org\/10.1007\/s00428-016-2030-x.","journal-title":"Virchows Arch"},{"issue":"1","key":"3274_CR23","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1182\/blood-2003-12-4197","volume":"104","author":"WY Au","year":"2004","unstructured":"Au WY, Pang A, Choy C, Chim CS, Kwong YL. Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood. 2004;104(1):243\u20139. https:\/\/doi.org\/10.1182\/blood-2003-12-4197.","journal-title":"Blood"},{"issue":"1","key":"3274_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.hbpd.2019.12.005","volume":"19","author":"T Qin","year":"2020","unstructured":"Qin T, Gu XQ, Jeong SS, Song YY, Liu JC, Zheng JX, et al. Impact of EBV infection and immune function assay for lymphoproliferative disorder in pediatric patients after liver transplantation: a single-center experience. Hepatobiliary Pancreat Dis Int. 2020;19(1):3\u201311. https:\/\/doi.org\/10.1016\/j.hbpd.2019.12.005.","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"3274_CR25","doi-asserted-by":"publisher","first-page":"237","DOI":"10.2176\/jns-nmc.2022-0091","volume":"9","author":"M Mizushima","year":"2022","unstructured":"Mizushima M, Ishi Y, Ikeda H, Echizenya I, Otsuka T, Mitsuhashi T, et al. Successful treatment of intracranial methotrexate-associated lymphoproliferative disorder without Epstein-Barr virus infection using Rituximab, Methotrexate, Procarbazine, and Vincristine: a case report. NMC Case Rep J. 2022;9:237\u201342. https:\/\/doi.org\/10.2176\/jns-nmc.2022-0091.","journal-title":"NMC Case Rep J"},{"key":"3274_CR26","doi-asserted-by":"publisher","first-page":"1059133","DOI":"10.3389\/fimmu.2022.1059133","volume":"13","author":"S Chakravorty","year":"2022","unstructured":"Chakravorty S, Afzali B, Kazemian M. EBV-associated diseases: current therapeutics and emerging technologies. Front Immunol. 2022;13:1059133. https:\/\/doi.org\/10.3389\/fimmu.2022.1059133.","journal-title":"Front Immunol"},{"issue":"4","key":"3274_CR27","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1111\/cas.13954","volume":"110","author":"T Kanda","year":"2019","unstructured":"Kanda T, Yajima M, Ikuta K. Epstein-Barr virus strain variation and cancer. Cancer Sci. 2019;110(4):1132\u20139. https:\/\/doi.org\/10.1111\/cas.13954.","journal-title":"Cancer Sci"},{"issue":"11","key":"3274_CR28","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1007\/s00277-005-1093-6","volume":"84","author":"S De Vita","year":"2005","unstructured":"De Vita S, De Matteis S, Laurenti L, Chiusolo P, Reddiconto G, Fiorini A, et al. Secondary Ph+ acute lymphoblastic leukemia after temozolomide. Ann Hematol. 2005;84(11):760\u20132. https:\/\/doi.org\/10.1007\/s00277-005-1093-6.","journal-title":"Ann Hematol"},{"key":"3274_CR29","doi-asserted-by":"publisher","DOI":"10.1111\/neup.12863","author":"F Ohgaki","year":"2022","unstructured":"Ohgaki F, Takemoto Y, Paku S, Tatezuki J, Kumagai J, Shuto T, et al. Primary central nervous system other iatrogenic immunodeficiency-associated lymphoproliferative disorders presenting as extraosseous plasmacytoma with a progressive clinical course: a case report and literature review. Neuropathology. 2022. https:\/\/doi.org\/10.1111\/neup.12863.","journal-title":"Neuropathology"},{"issue":"14","key":"3274_CR30","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","volume":"328","author":"RI Fisher","year":"1993","unstructured":"Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin\u2019s lymphoma. N Engl J Med. 1993;328(14):1002\u20136. https:\/\/doi.org\/10.1056\/NEJM199304083281404.","journal-title":"N Engl J Med"},{"issue":"1","key":"3274_CR31","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1080\/14397595.2018.1472358","volume":"29","author":"H Kameda","year":"2019","unstructured":"Kameda H, Fujii T, Nakajima A, Koike R, Sagawa A, Kanbe K, et al. Japan College of Rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis. Mod Rheumatol. 2019;29(1):31\u201340. https:\/\/doi.org\/10.1080\/14397595.2018.1472358.","journal-title":"Mod Rheumatol"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-023-03274-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-023-03274-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-023-03274-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T03:02:24Z","timestamp":1686279744000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-023-03274-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,9]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3274"],"URL":"https:\/\/doi.org\/10.1186\/s12883-023-03274-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2563990\/v1","asserted-by":"object"}]},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,9]]},"assertion":[{"value":"8 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the institutional review board (#2231).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent from the patient was obtained for publication of identifying information\/images in an online open-access publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"224"}}